144 related articles for article (PubMed ID: 31724562)
1. Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma.
Liu S; Li C; Xin P; Zheng Y; Peng Q; Xu Y; Luo Y; Wu Y; Zhu X
Med Sci Monit; 2019 Nov; 25():8579-8586. PubMed ID: 31724562
[TBL] [Abstract][Full Text] [Related]
2. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties.
Wang F; Stappenbeck F; Parhami F
Cells; 2019 May; 8(5):. PubMed ID: 31137846
[TBL] [Abstract][Full Text] [Related]
4. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line.
Zhao F; Wang J; Yao L; Qin YT; Tuerxun N; Wang H; Jiang M; Hao JP
Hematology; 2021 Dec; 26(1):518-528. PubMed ID: 34314648
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Stathis A; Hess D; von Moos R; Homicsko K; Griguolo G; Joerger M; Mark M; Ackermann CJ; Allegrini S; Catapano CV; Xyrafas A; Enoiu M; Berardi S; Gargiulo P; Sessa C;
Invest New Drugs; 2017 Dec; 35(6):766-772. PubMed ID: 28317088
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.
Dagklis A; Demeyer S; De Bie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; de Bock CE; Cools J
Blood; 2016 Dec; 128(23):2642-2654. PubMed ID: 27694322
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma.
Liu P; Chen L
Leuk Res; 2018 Jan; 64():1-9. PubMed ID: 29132010
[TBL] [Abstract][Full Text] [Related]
9. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
10. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.
Wickström M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevåg OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI
Int J Cancer; 2013 Apr; 132(7):1516-24. PubMed ID: 22949014
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
12. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
13. Role of Hedgehog-Gli1 signaling in the enhanced proliferation and differentiation of MG63 cells enabled by hierarchical micro-/nanotextured topography.
Lin Y; Huang Y; He J; Chen F; He Y; Zhang W
Int J Nanomedicine; 2017; 12():3267-3280. PubMed ID: 28458545
[TBL] [Abstract][Full Text] [Related]
14. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
15. WP1066 exhibits antitumor efficacy in nasal‑type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway.
Geng L; Li X; Zhou X; Fang X; Yuan D; Wang X
Oncol Rep; 2016 Nov; 36(5):2868-2874. PubMed ID: 27633398
[TBL] [Abstract][Full Text] [Related]
16. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
17. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
18. GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3.
Geng L; Lu K; Li P; Li X; Zhou X; Li Y; Wang X
Oncotarget; 2017 Jul; 8(30):48701-48710. PubMed ID: 27275540
[TBL] [Abstract][Full Text] [Related]
19. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
